2 years from 0.17 to 200,000,000 yuan leap - New Friends Tanreqing injection successfully resolved.docVIP

 PAGE \* MERGEFORMAT 9 2 years from 0.17 to 200,000,000 yuan leap - New Friends Tanreqing injection successfully resolved Only two years, was 10-speed Tanreqing sales growth, jumped the brand of proprietary Chinese medicines for respiratory Top Championship. Where is the secret of its success? ‘To be a’ blockbuster ‘to us’ In April 2005, due to the successful planning of the ‘Tiopronin’ brand refresh project. Xinyi Medicine Group, again exclusive varieties ‘Tanreqing injection’ to the case plan, entrusted to Baiqing medical marketing agency. They asked is: ‘to be a’ blockbuster ‘to us! ‘ Tanreqing injection, R amp;amp; D 8 years, input billion, 03 year-end market was rated as ‘anti-SARS focus on new product’ award. Is China’s first use of ‘traditional Chinese medicine fingerprinting technology’ production of traditional Chinese medicine injections. Standards, compatibility, process, quality control and so on, are all efforts to innovate. Validity, clarity, security, stability, both the breakthrough. Product rests with the similar products in the absolute leader. Market, the increasing incidence of chronic bronchitis, etc., the market capacity growth; Yuxingcao injection products such as manufacturers scattered, without a strong brand, pharmaceutical standards and low, the craft behind the high rate of adverse reactions, product left plenty of room for modernization. In contrast the new-Yi, the channel network across the country, stability, strong hospital terminal, execution, strong marketing team, even if only these elements, Tanreqing injection can also be growing steadily. Prescription drug market in the past emphasis on sales, marketing, light; re-driven, light pull; randomness strong, weak integration. Tanreqing injection to be successful, it must break through the above drawbacks. To this end, Bai-qing set three strategic directions: First, we must systematically plan, from the ‘clinical value to enhance doctors’ departure, good product posi